Lyell Immunopharma, Inc. Profile Avatar - Palmy Investing

Lyell Immunopharma, Inc.

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to over…

Biotechnology
US, South San Francisco [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Lyell Immunopharma, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Lyell Immunopharma, Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Lyell Immunopharma, Inc..

End of LYEL's Analysis
CIK: 1806952 CUSIP: 55083R104 ISIN: US55083R1041 LEI: - UEI: -
Secondary Listings
LYEL has no secondary listings inside our databases.